Vaginal Lactoferrin Administration Decreases Oxidative Stress in the Amniotic Fluid of Pregnant Women: An Open-Label Randomized Pilot Study
Background: Oxidative stress (OxS) has been linked to several pregnancy-related complications. Previous studies demonstrated that lactoferrin (LF) has the ability to modulate inflammation, OxS and the immune function. Therefore, we aimed to observe whether vaginal LF administration was able to decre...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-09-01
|
Series: | Frontiers in Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fmed.2020.00555/full |
id |
doaj-fd77f8ec23264f068e3e0d9f6b0e09bb |
---|---|
record_format |
Article |
spelling |
doaj-fd77f8ec23264f068e3e0d9f6b0e09bb2020-11-25T02:53:01ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2020-09-01710.3389/fmed.2020.00555565572Vaginal Lactoferrin Administration Decreases Oxidative Stress in the Amniotic Fluid of Pregnant Women: An Open-Label Randomized Pilot StudyAlessandro Trentini0Martina Maritati1Valentina Rosta2Carlo Cervellati3Maria Cristina Manfrinato4Stefania Hanau5Pantaleo Greco6Gloria Bonaccorsi7Tiziana Bellini8Carlo Contini9Section of Medical Biochemistry, Molecular Biology and Genetics, Department of Biomedical and Specialist Surgical Sciences, University of Ferrara, Ferrara, ItalySection of Dermatology and Infectious Diseases, Department of Medical Sciences, University of Ferrara, Ferrara, ItalySection of Medical Biochemistry, Molecular Biology and Genetics, Department of Biomedical and Specialist Surgical Sciences, University of Ferrara, Ferrara, ItalyDepartment of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, ItalySection of Medical Biochemistry, Molecular Biology and Genetics, Department of Biomedical and Specialist Surgical Sciences, University of Ferrara, Ferrara, ItalySection of Medical Biochemistry, Molecular Biology and Genetics, Department of Biomedical and Specialist Surgical Sciences, University of Ferrara, Ferrara, ItalySection of Orthopedics, Obstetrics and Gynecology and Anesthesia and Resuscitation, Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, ItalySection of Orthopedics, Obstetrics and Gynecology and Anesthesia and Resuscitation, Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, ItalySection of Medical Biochemistry, Molecular Biology and Genetics, Department of Biomedical and Specialist Surgical Sciences, University of Ferrara, Ferrara, ItalySection of Dermatology and Infectious Diseases, Department of Medical Sciences, University of Ferrara, Ferrara, ItalyBackground: Oxidative stress (OxS) has been linked to several pregnancy-related complications. Previous studies demonstrated that lactoferrin (LF) has the ability to modulate inflammation, OxS and the immune function. Therefore, we aimed to observe whether vaginal LF administration was able to decrease OxS in the amniotic fluid (AF) of pregnant women undergoing mid-trimester genetic amniocentesis.Methods: In this open-label clinical study, 60 pregnant women were divided into three groups: CONTROLS (n = 20), not treated with LF; LACTO 4HRS (n = 20), treated with LF 4 h prior to amniocentesis; LACTO 12HRS (n = 20), treated with LF 12 h prior to amniocentesis. Thiobarbituric acid reactive substances (TBARS), total antioxidant status (TAS) and oxidative stress index (OSI) were measured in AF samples. In addition, the in vitro antioxidant activity of LF on a cell line was tested.Results: LF decreased the concentration of TBARS in the AF, with LACTO 4HRS demonstrating the lowest value compared with CONTROLS (P < 0.0001). LACTO 4HRS had higher TAS and lower OSI than CONTROLS (P < 0.0001 for both). In vitro, LF was effective against the oxidative challenge regardless of the time of pretreatment.Conclusion: In conclusion, LF decreased both in vivo and in vitro OxS. LF administration may represent an intriguing clinical solution as an adjuvant to treat complications of pregnancy related to inflammation and OxS.Trial Registration:Clinicaltrials.gov, NCT02695563. Registered 01 March 2016—Retrospectively registered, https://clinicaltrials.gov/show/NCT02695563.https://www.frontiersin.org/article/10.3389/fmed.2020.00555/fulllactoferrinoxidative stressinflammationamniotic fluidpregnancy complications |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Alessandro Trentini Martina Maritati Valentina Rosta Carlo Cervellati Maria Cristina Manfrinato Stefania Hanau Pantaleo Greco Gloria Bonaccorsi Tiziana Bellini Carlo Contini |
spellingShingle |
Alessandro Trentini Martina Maritati Valentina Rosta Carlo Cervellati Maria Cristina Manfrinato Stefania Hanau Pantaleo Greco Gloria Bonaccorsi Tiziana Bellini Carlo Contini Vaginal Lactoferrin Administration Decreases Oxidative Stress in the Amniotic Fluid of Pregnant Women: An Open-Label Randomized Pilot Study Frontiers in Medicine lactoferrin oxidative stress inflammation amniotic fluid pregnancy complications |
author_facet |
Alessandro Trentini Martina Maritati Valentina Rosta Carlo Cervellati Maria Cristina Manfrinato Stefania Hanau Pantaleo Greco Gloria Bonaccorsi Tiziana Bellini Carlo Contini |
author_sort |
Alessandro Trentini |
title |
Vaginal Lactoferrin Administration Decreases Oxidative Stress in the Amniotic Fluid of Pregnant Women: An Open-Label Randomized Pilot Study |
title_short |
Vaginal Lactoferrin Administration Decreases Oxidative Stress in the Amniotic Fluid of Pregnant Women: An Open-Label Randomized Pilot Study |
title_full |
Vaginal Lactoferrin Administration Decreases Oxidative Stress in the Amniotic Fluid of Pregnant Women: An Open-Label Randomized Pilot Study |
title_fullStr |
Vaginal Lactoferrin Administration Decreases Oxidative Stress in the Amniotic Fluid of Pregnant Women: An Open-Label Randomized Pilot Study |
title_full_unstemmed |
Vaginal Lactoferrin Administration Decreases Oxidative Stress in the Amniotic Fluid of Pregnant Women: An Open-Label Randomized Pilot Study |
title_sort |
vaginal lactoferrin administration decreases oxidative stress in the amniotic fluid of pregnant women: an open-label randomized pilot study |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Medicine |
issn |
2296-858X |
publishDate |
2020-09-01 |
description |
Background: Oxidative stress (OxS) has been linked to several pregnancy-related complications. Previous studies demonstrated that lactoferrin (LF) has the ability to modulate inflammation, OxS and the immune function. Therefore, we aimed to observe whether vaginal LF administration was able to decrease OxS in the amniotic fluid (AF) of pregnant women undergoing mid-trimester genetic amniocentesis.Methods: In this open-label clinical study, 60 pregnant women were divided into three groups: CONTROLS (n = 20), not treated with LF; LACTO 4HRS (n = 20), treated with LF 4 h prior to amniocentesis; LACTO 12HRS (n = 20), treated with LF 12 h prior to amniocentesis. Thiobarbituric acid reactive substances (TBARS), total antioxidant status (TAS) and oxidative stress index (OSI) were measured in AF samples. In addition, the in vitro antioxidant activity of LF on a cell line was tested.Results: LF decreased the concentration of TBARS in the AF, with LACTO 4HRS demonstrating the lowest value compared with CONTROLS (P < 0.0001). LACTO 4HRS had higher TAS and lower OSI than CONTROLS (P < 0.0001 for both). In vitro, LF was effective against the oxidative challenge regardless of the time of pretreatment.Conclusion: In conclusion, LF decreased both in vivo and in vitro OxS. LF administration may represent an intriguing clinical solution as an adjuvant to treat complications of pregnancy related to inflammation and OxS.Trial Registration:Clinicaltrials.gov, NCT02695563. Registered 01 March 2016—Retrospectively registered, https://clinicaltrials.gov/show/NCT02695563. |
topic |
lactoferrin oxidative stress inflammation amniotic fluid pregnancy complications |
url |
https://www.frontiersin.org/article/10.3389/fmed.2020.00555/full |
work_keys_str_mv |
AT alessandrotrentini vaginallactoferrinadministrationdecreasesoxidativestressintheamnioticfluidofpregnantwomenanopenlabelrandomizedpilotstudy AT martinamaritati vaginallactoferrinadministrationdecreasesoxidativestressintheamnioticfluidofpregnantwomenanopenlabelrandomizedpilotstudy AT valentinarosta vaginallactoferrinadministrationdecreasesoxidativestressintheamnioticfluidofpregnantwomenanopenlabelrandomizedpilotstudy AT carlocervellati vaginallactoferrinadministrationdecreasesoxidativestressintheamnioticfluidofpregnantwomenanopenlabelrandomizedpilotstudy AT mariacristinamanfrinato vaginallactoferrinadministrationdecreasesoxidativestressintheamnioticfluidofpregnantwomenanopenlabelrandomizedpilotstudy AT stefaniahanau vaginallactoferrinadministrationdecreasesoxidativestressintheamnioticfluidofpregnantwomenanopenlabelrandomizedpilotstudy AT pantaleogreco vaginallactoferrinadministrationdecreasesoxidativestressintheamnioticfluidofpregnantwomenanopenlabelrandomizedpilotstudy AT gloriabonaccorsi vaginallactoferrinadministrationdecreasesoxidativestressintheamnioticfluidofpregnantwomenanopenlabelrandomizedpilotstudy AT tizianabellini vaginallactoferrinadministrationdecreasesoxidativestressintheamnioticfluidofpregnantwomenanopenlabelrandomizedpilotstudy AT carlocontini vaginallactoferrinadministrationdecreasesoxidativestressintheamnioticfluidofpregnantwomenanopenlabelrandomizedpilotstudy |
_version_ |
1724727183487795200 |